Misconceptions about calcimimetics

被引：23

作者：

Nemeth, E. F. ^{[1
]}

机构：

[1] NPS Pharmaceut Inc, Toronto, ON M5G 1L8, Canada

来源：

SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING | 2006年 / 1068卷

关键词：

calcimimetics; calcium receptor; allosteric modulators; drug discovery;

D O I：

10.1196/annals.1346.044

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Calcimimetics are ligands that activate the calcium receptor. Some are small molecules and of these, the most extensively studied are phenylalkylamines like cinacalcet. This compound is a positive allosteric modulator that selectively targets the parathyroid calcium receptor to inhibit the secretion of parathyroid hormone. Cinacalcet is the first calcimimetic compound to attain regulatory approval for the treatment of hyperparathyroidism resulting from end-stage renal disease. The discovery of calcimimetics and the receptor they act on are considered with the intent of extracting lessons relevant to medical research and the discovery of new drugs.

引用

页码：471 / 476

页数：6

共 50 条

[41] Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Zitt, Emanuel
Rosenkranz, Alexander R.
CURRENT DRUG THERAPY, 2006, 1 (02) : 147 - 155
[42] Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis
Fukunaga, Shohei
Egawa, Masahiro
Shiono, Manabu
Ito, Takafumi
Tanabe, Kazuaki
CLINICAL NEPHROLOGY, 2023, 100 (02) : 60 - 66
[43] Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials
Wakamatsu, Takuya
Yamamoto, Suguru
Matsuo, Koji
Taniguchi, Masatomo
Hamano, Takayuki
Fukagawa, Masafumi
Kazama, Junichiro James
JOURNAL OF BONE AND MINERAL METABOLISM, 2024, 42 (03) : 316 - 325
[44] Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis
Koh, Ezra Y.
van der Plas, Willemijn Y.
Dulfer, Roderick R.
Pol, Robert A.
Kruijf, Schelto
Rotmans, Joris I.
Appelman-Dijkstra, Natasha
Schepers, Abbey
de Borst, Martin H.
Hoorn, Ewout J.
van Ginhoven, Tessa
Nieveen van Dijkum, Els J. M.
Vogt, Liffert
Engelsman, Anton F.
LANGENBECKS ARCHIVES OF SURGERY, 2020, 405 (06) : 851 - 859
[45] Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis
Drüeke, TB
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 20 - 22
[46] The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease
Block, GA
KIDNEY INTERNATIONAL, 2003, 64 : S131 - S136
[47] Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means
Drüeke, TB
PEDIATRIC NEPHROLOGY, 2005, 20 (03) : 399 - 403
[48] Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease
Lindberg, JS
KIDNEY INTERNATIONAL, 2005, 67 : S33 - S36
[49] Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action
Henaut, Lucie
Boudot, Cedric
Massy, Ziad A.
Lopez-Fernandez, Irene
Dupont, Sebastien
Mary, Aurelien
Drueeke, Tilman B.
Kamel, Said
Brazier, Michel
Mentaverri, Romuald
CARDIOVASCULAR RESEARCH, 2014, 101 (02) : 256 - 265
[50] Functional proteins involved in regulation of intracellular Ca2+ for drug development:: The extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics
Nagano, N
Nemeth, EF
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 (03) : 355 - 360

← 1 2 3 4 5 →